We are live on ! Find out more
BLRX

BioLineRX
BLRX

12 hedge funds and large institutions have $8.01M invested in BioLineRX in 2013 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

57% more capital invested

Capital invested by funds: $5.12M → $8.01M (+$2.89M)

20% more funds holding

Funds holding: 10 → 12 (+2)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
12
Holders Change
+2
Holders Change %
+20%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
+$105K
2
UBS AM
UBS AM
Illinois
+$80.6K
3
ARTA
A.R.T. Advisors
New York
+$27.4K
4
TRCT
Tower Research Capital (TRC)
New York
+$22.6K
5
VKH
Virtu KCG Holdings
New York
+$6.45K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$537K
2
Deutsche Bank
Deutsche Bank
Germany
-$163K
3
Renaissance Technologies
Renaissance Technologies
New York
-$139K
4
Citigroup
Citigroup
New York
-$1.61K

BLRX Hedge Fund Activity: Q4 2013 in Review

12 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2013, worth a combined $8.01M — up 57% from $5.12M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BLRX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Senvest Management, adding an estimated $105K. The largest seller was OrbiMed, cutting an estimated $537K.

  • 12 institutional investors held BioLineRX (BLRX) as of Q4 2013, up from 10 in Q3 2013.
  • Funds reported $8.01M of BioLineRX stock for Q4 2013, up 57% quarter-over-quarter.
  • 3 funds opened new BioLineRX positions in Q4 2013 and 1 closed out, a net change of +2 holders.
  • The largest BioLineRX buyer in Q4 2013 was Senvest Management, an estimated $105K added.
  • The largest BioLineRX seller in Q4 2013 was OrbiMed, an estimated $537K sold.

Based on aggregated 13F filings for Q4 2013.